Considerations for implementation of vancomycin Bayesian software monitoring in a level IV NICU population within a multisite health system.

Purpose The updated 2020 vancomycin therapeutic drug monitoring guideline advocates for area under the curve (AUC)–based monitoring in neonates, preferably with Bayesian estimation. This article describes the selection, planning, and implementation of vancomycin model-informed precision dosing (MIPD...

Descripción completa

Detalles Bibliográficos
Publicado en:American Journal of Health-System Pharmacy Vol. 80; no. 11; pp. 670 - 678
Autores principales: Oliver, Meredith B, Boeser, Kimberly D, Carlson, Melissa K, Hansen, Lizbeth A
Formato: tables/charts Journal Article
Publicado: Oxford University Press / USA Jun2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=163926902&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 163926902
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10792082
        1X3
      jtl: American Journal of Health-System Pharmacy
      issn: 10792082
      maglogo: N
    pubinfo:
      dt: Jun2023
      vid: 80
      iid: 11
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        163926902
        163926902
        163926902
        10.1093/ajhp/zxad048
        163926902
      ppf: 670
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Considerations for implementation of vancomycin Bayesian software monitoring in a level IV NICU population within a multisite health system.
      aug:
        au:
          Oliver, Meredith B
          Boeser, Kimberly D
          Carlson, Melissa K
          Hansen, Lizbeth A
        affil: Department of Pharmacy, M Health Fairview Masonic Children's Hospital , Minneapolis, MN , USA
      sug:
        subj:
          Vancomycin Pharmacokinetics
          Intensive Care Units, Neonatal
          Software
          Program Implementation
          Neonatal Assessment
          Drug Monitoring
          Practice Guidelines
          Information Resources
          Models, Statistical
          Program Planning
          Mobile Applications
      ab: Purpose The updated 2020 vancomycin therapeutic drug monitoring guideline advocates for area under the curve (AUC)–based monitoring in neonates, preferably with Bayesian estimation. This article describes the selection, planning, and implementation of vancomycin model-informed precision dosing (MIPD) software with Bayesian estimation in the neonatal intensive care unit (NICU) within an academic health system. Summary The selection, planning, and implementation of vancomycin MIPD software was completed in approximately 6 months throughout a health system with multiple NICU sites. The chosen software captures data on medications in additional to vancomycin, provides analytics support, includes specialty populations (eg, neonates), and offers the ability to integrate MIPD into the electronic health record. Pediatric pharmacy representatives served on a system-wide project team with key responsibilities including development of educational materials, drafting changes to policies and procedures, and assistance with department-wide software training. Additionally, pediatric and neonatal pharmacist super users trained other pediatric pharmacists on software functionality, were available the week of go-live for in-person support, and contributed to the identification of pediatric and NICU-specific nuances related to software implementation. Neonatal-specific considerations when implementing MIPD software include: the selection of appropriate pharmacokinetic model(s), continued evaluation of such model(s), selection of appropriate model(s) in infants as they age, input of significant covariates, determination of the site-specific serum creatinine assay, decision of the number of vancomycin serum concentrations obtained, discernment of patients excluded from AUC monitoring, and the utilization of actual versus dosing weight. Conclusion This article serves to share our experience with selecting, planning, and implementing Bayesian software for vancomycin AUC monitoring in a neonatal population. Other health systems and children's hospitals can utilize our experience to evaluate a variety of MIPD software and consider neonatal nuances prior to implementation.
      pubtype: Academic Journal
      doctype:
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N